NDAINTRAVENOUSSOLUTION
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
7/8 — Comprehensive
AKYNZEO (fosnetupitant and palonosetron) by Helsinn is serotonin 3 receptor antagonists [moa]. Approved for combination with dexamethasone in adults for the prevention of acute, delayed nausea, vomiting associated with initial and 5 more indications. First approved in 2018.
Drug data last refreshed 23h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKYNZEO is a fixed-dose combination of fosnetupitant (a neurokinin-1 receptor antagonist) and palonosetron (a serotonin-3 receptor antagonist) administered intravenously. It prevents acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy when combined with dexamethasone. This dual-mechanism antiemetic targets multiple pathways involved in chemotherapy-induced nausea and vomiting (CINV).
$0.441MPart D
Peak10.6 years to LOEAKYNZEO is in peak commercial phase with modest Medicare Part D utilization, indicating a mature, stable oncology supportive care product with limited growth trajectory.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Pharmacologic Class:
Serotonin-3 Receptor Antagonist
Worked on AKYNZEO at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.